ARVN
Arvinas·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARVN
Arvinas, Inc.
A clinical-stage biotechnology company that developing therapies to degrade disease-causing proteins
5 Science Park, 395 Winchester Ave., New Haven, Connecticut 06511
--
Arvinas, Inc., was incorporated in February 2013 under the laws of the State of Delaware. The company is a biopharmaceutical company dedicated to improving the lives of patients with debilitating and life-threatening diseases by discovering, developing and commercializing treatments to reduce disease-causing proteins. The company uses their proprietary technology platform to design proteolysis for chimeras, or PROTACs, which are designed to utilize the body's own natural protein processing system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas Holding Company, LLC believes that their targeted protein degradation approach is a new therapeutic modality that may offer unique advantages over existing modalities, including traditional small molecule therapies and gene-based medicines.
Earnings Call
Q1/2025
Estimate EPS-0.97
Actual EPS1.14
Estimate Revenue41.87M
Actual Revenue188.80M
Contradictions Unveiled: Arvinas' Q1 2025 Earnings Call on CDK4/6 Combinations, Market Size, and Trial Strategies
May 02,2025 12:49
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.89
Actual EPS-0.84
Estimate Revenue34.42M
Actual Revenue22.40M
Arvinas' Q2 2025: Navigating Key Contradictions in Parkinson's Treatment Strategies and Clinical Progress
Aug 06,2025 01:30
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ARVN has released its 2025 Q3 earnings. EPS was reported at -0.48, versus the expected -0.75, beating expectations. The chart below visualizes how ARVN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ARVN has released its 2025 Q3 earnings report, with revenue of 41.90M, reflecting a YoY change of -59.08%, and net profit of -35.10M, showing a YoY change of 28.66%. The Sankey diagram below clearly presents ARVN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
